XNYS
RVTY
Market cap12bUSD
Jul 09, Last price
112.95USD
1D
3.29%
1Q
25.79%
Jan 2017
116.59%
Name
Perkinelmer Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PerkinElmer, Inc. operates as a global enterprise delivering innovative products, specialized services, and comprehensive solutions across the diagnostics, life sciences, and applied technology sectors. The company's operations are divided into two main segments: Discovery & Analytical Solutions, and Diagnostics. The Discovery & Analytical Solutions division furnishes scientists with an extensive suite of offerings, including chemical reagents, informatics platforms, and cutting-edge detection and imaging technologies. These resources are designed to accelerate research breakthroughs in the life sciences, and the segment also provides contract research and laboratory services. Additionally, it supplies analytical technologies, integrated solutions, and expert services to clients in the environmental, food, and industrial markets, aiding in the assessment and characterization of air, water, and soil quality. This segment further supports agricultural producers and food manufacturers, and delivers analytical instrumentation to a broad spectrum of industrial clients, encompassing chemical, semiconductor, electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment specializes in providing essential instruments, reagents, assay platforms, and software products for the early identification of genetic disorders, particularly during pregnancy and early childhood, as well as for infectious disease screening. Its product range facilitates the testing and detection of various genetic abnormalities and conditions, such as Down syndrome, hypothyroidism, muscular dystrophy, infertility, and diverse metabolic disorders. Moreover, this segment develops enabling technologies that support advanced genomic workflows, leveraging methods like G-protein coupled receptor (GPCR) analysis and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery research. PerkinElmer's client base is diverse, including pharmaceutical and biotechnology companies, research laboratories, academic and scientific institutions, public health organizations, private healthcare providers, medical professionals, and governmental agencies. Founded in 1937, PerkinElmer, Inc. is headquartered in Waltham, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||